ZVRA Zevra Therapeutics, Inc. Net earnings per share for the last 12 months

Zevra Therapeutics (ZVRA) trailing 12-month profit per unit demonstrates the company's transition toward stable commercial revenues in the US. The business relies on the market launch of orphan drugs and a diversified pipeline. The integration of scientific platforms with patient support creates a closed-loop cycle for neurological disorder therapy. Consequently, 1.19 becomes the new value for this metric, confirming current financial efficiency.
Zevra Corp - analytical breakdowns and key metrics (ZVRA)

Trailing twelve-month earnings per share measures the owner's share of net income adjusted for the total volume of issuance, allowing for an objective assessment of business capitalization efficiency. By analyzing the trailing twelve-month earnings per share trend, an investor can diagnose the financial stability of Zevra Therapeutics (ZVRA), whose profitability is protected by exclusive FDA orphan drug rights and patent barriers.